Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US-9452227-B2 · Sep 27, 2016 · US
Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody
US9725509B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9725509-B2 |
| Application number | US-201514604366-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2015 |
| Priority date | May 21, 2007 |
| Publication date | Aug 8, 2017 |
| Grant date | Aug 8, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.
First claim
Opening claim text (preview).
What is claimed is: 1. A vector containing an isolated nucleic acid that encodes for an anti-human interleukin-6 (“IL-6”) antibody or antigen-binding fragment wherein the anti-human IL-6 antibody or antibody fragment comprises: a variable light (V L ) region comprising complementarity region CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:4, 5 and 6, and a variable heavy (V H ) region comprising complementarity region CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:7, 8 or 120 and 9. 2. The vector of claim 1 , wherein the V L region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:4, 5 and 6, and the V H region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:7, 120 and 9. 3. The vector of claim 1 , wherein the V L region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:4, 5 and 6, and the V H region comprises CDR1, CDR2 and CDR3 polypeptides, respectively having the sequences of SEQ ID NO:7, 8 and 9. 4. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 90% identical to a polypeptide having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6. 5. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 90% identical to the to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9. 6. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 90% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9. 7. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 90% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 90% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 120 and 9. 8. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 90% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 90% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 8 and 9. 9. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 95% identical to a polypeptide having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6. 10. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 95% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9. 11. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 95% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9. 12. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 95% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 95% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 120 and 9. 13. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 95% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 95% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 8 and 9. 14. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 98% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9. 15. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is at least 98% identical to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9. 16. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 98% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 98% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 120 and 9. 17. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is at least 98% identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is at least 98% identical to the heavy chain framework region having the sequence of SEQ ID NO:18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:7, 8 and 9. 18. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is identical to the to a polypeptide having the sequence of SEQ ID NO: 18 or 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 120 and 9. 19. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is identical to the to a polypeptide having the sequence of SEQ ID NO: 19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9. 20. The vector of claim 1 , wherein the variable heavy chain comprises a polypeptide which is identical to a polypeptide having the sequence of SEQ ID NO: 18 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO: 7, 8 and 9. 21. The vector of claim 1 , wherein the variable light chain comprises a polypeptide which is identical to the light chain framework region having the sequence of SEQ ID NO:20 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID NO:4, 5 and 6 and the variable heavy chain comprises a polypeptide which is identical to the heavy chain framework region having the sequence of SEQ ID NO:19 and further comprising the CDR1, CDR2 and CDR3 polypeptides of SEQ ID
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
comprising antibodies · CPC title
derived from animal tissue · CPC title
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9725509B2 cover?
- The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.
- Who is the assignee on this patent?
- Alderbio Holdings Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/248. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).